IN2014DN08088A - - Google Patents

Info

Publication number
IN2014DN08088A
IN2014DN08088A IN8088DEN2014A IN2014DN08088A IN 2014DN08088 A IN2014DN08088 A IN 2014DN08088A IN 8088DEN2014 A IN8088DEN2014 A IN 8088DEN2014A IN 2014DN08088 A IN2014DN08088 A IN 2014DN08088A
Authority
IN
India
Prior art keywords
oil
prophylaxis
treatment
water emulsion
neurological damage
Prior art date
Application number
Other languages
English (en)
Inventor
Ilona Kaspar
Volker Krüger
Doris Röthlein
Jürgen Schmitt
Martin Wolf
Original Assignee
Braun Melsungen Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Braun Melsungen Ag filed Critical Braun Melsungen Ag
Publication of IN2014DN08088A publication Critical patent/IN2014DN08088A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/107Emulsions ; Emulsion preconcentrates; Micelles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/107Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IN8088DEN2014 2012-02-29 2013-02-25 IN2014DN08088A (enrdf_load_stackoverflow)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12157546 2012-02-29
PCT/EP2013/053679 WO2013127727A1 (en) 2012-02-29 2013-02-25 Hormone containing emulsion comprising krill phospholipids

Publications (1)

Publication Number Publication Date
IN2014DN08088A true IN2014DN08088A (enrdf_load_stackoverflow) 2015-05-01

Family

ID=47748635

Family Applications (2)

Application Number Title Priority Date Filing Date
IN8088DEN2014 IN2014DN08088A (enrdf_load_stackoverflow) 2012-02-29 2013-02-25
IN8089DEN2014 IN2014DN08089A (enrdf_load_stackoverflow) 2012-02-29 2013-02-25

Family Applications After (1)

Application Number Title Priority Date Filing Date
IN8089DEN2014 IN2014DN08089A (enrdf_load_stackoverflow) 2012-02-29 2013-02-25

Country Status (16)

Country Link
US (2) US20150018320A1 (enrdf_load_stackoverflow)
EP (2) EP2819650A1 (enrdf_load_stackoverflow)
JP (2) JP6169110B2 (enrdf_load_stackoverflow)
KR (2) KR102027613B1 (enrdf_load_stackoverflow)
CN (3) CN104136007A (enrdf_load_stackoverflow)
BR (2) BR112014021391B1 (enrdf_load_stackoverflow)
CA (2) CA2865030C (enrdf_load_stackoverflow)
ES (1) ES2659466T3 (enrdf_load_stackoverflow)
IL (2) IL233759B (enrdf_load_stackoverflow)
IN (2) IN2014DN08088A (enrdf_load_stackoverflow)
MX (2) MX356427B (enrdf_load_stackoverflow)
NO (1) NO2819649T3 (enrdf_load_stackoverflow)
PL (1) PL2819649T3 (enrdf_load_stackoverflow)
PT (1) PT2819649T (enrdf_load_stackoverflow)
RU (2) RU2014139008A (enrdf_load_stackoverflow)
WO (2) WO2013127728A1 (enrdf_load_stackoverflow)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6285866B2 (ja) 2011-11-23 2018-02-28 セラピューティックスエムディー インコーポレーテッドTherapeuticsmd, Inc. 天然複合ホルモン補充製剤および療法
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US9486433B2 (en) 2012-10-12 2016-11-08 Mochida Pharmaceuticals Co. Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10441560B2 (en) 2013-03-15 2019-10-15 Mochida Pharmaceutical Co., Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
AU2014230444B2 (en) 2013-03-15 2018-05-17 Mochida Pharmaceutical Co., Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
KR101588247B1 (ko) * 2013-04-17 2016-01-25 경희대학교 산학협력단 뇌졸중 또는 퇴행성 뇌질환 예방 또는 치료용 조성물
WO2015053379A1 (en) * 2013-10-07 2015-04-16 Mochida Pharmaceutical Co., Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
GB201402450D0 (en) 2014-02-12 2014-03-26 Aker Biomarine As Liquid phospholipid-containing compositions for preperation of pharmaceuticals
GB201402457D0 (en) 2014-02-12 2014-03-26 Aker Biomarine As Capsules containing high doses of phospholipids
GB201407345D0 (en) 2014-04-25 2014-06-11 Aker Biomarine As Krill Phospholipid compositions
US10206932B2 (en) 2014-05-22 2019-02-19 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
WO2016018993A1 (en) 2014-07-29 2016-02-04 Therapeuticsmd, Inc. Transdermal cream
WO2016097854A1 (en) 2014-12-19 2016-06-23 Aker Biomarine Antarctic As Enhanced omega-3 formulations
CA2971786A1 (en) * 2015-03-31 2016-10-06 Fresenius Kabi Deutschland Gmbh Emulsions for parenteral administration
GB201509606D0 (en) * 2015-06-03 2015-07-15 Anabio Technologies Ltd Microencapsulates containing stabilised marine-derived oil, and methods for production thereof
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
JP2019513709A (ja) 2016-04-01 2019-05-30 セラピューティックスエムディー インコーポレーテッドTherapeuticsmd, Inc. ステロイドホルモン薬学的組成物
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
CN105878184A (zh) * 2016-04-26 2016-08-24 天津市中升挑战生物科技有限公司 一种四烯雌酮纳米乳液及其制备方法
SG11202000592WA (en) * 2017-08-10 2020-02-27 Childrens Medical Ct Corp Methods and compositions relating to emulsions comprising fish oil and/or omega-3 fatty acids
US20230054162A1 (en) 2019-12-20 2023-02-23 Fresenius Kabi Austria Gmbh Methods for producing oil-in-water emulsions
EP4135684B1 (en) * 2020-04-15 2025-06-18 The Trustees of Columbia University in the City of New York Stable diglyceride emulsions and methods for treating organ injury
US20240050391A1 (en) * 2020-12-07 2024-02-15 The Trustees Of Columbia University In The City Of New York Compositions and methods for neuroprotection in neonatal hypoxic-ischemic encephalopathy
GB202316026D0 (en) * 2023-10-19 2023-12-06 Theramex Hq Uk Ltd Methods of prevention or treatment
DE102023128848A1 (de) * 2023-10-20 2025-04-24 Sativari UG (haftungsbeschränkt) Flüssige pharmazeutische Rezeptur zur intravenösen, subkutanen, oder intramuskulären Applikation einer oder mehrerer Cannabinoide
WO2025083197A1 (de) * 2023-10-20 2025-04-24 Sativari UG (haftungsbeschränkt) Flüssige pharmazeutische rezeptur zur intravenösen, subkutanen, oder intramuskulären applikation einer oder mehrerer cannabinoide

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2738253A1 (de) 1977-08-25 1979-03-01 Dabisch Tipp Ex Tech Koerper mit reversibel temperaturabhaengiger transparenz
DE2749265A1 (de) 1977-11-03 1979-05-10 Linde Ag Verfahren zur biologischen reinigung von abwasser
JPS60258110A (ja) 1984-06-05 1985-12-20 Daigo Eiyou Kagaku Kk 静脈注射可能なプロゲステロン乳化注射液
US5560364A (en) 1995-05-12 1996-10-01 The Board Of Regents Of The University Of Nebraska Suspended ultra-sound induced microbubble cavitation imaging
US20100173876A1 (en) 2000-12-19 2010-07-08 The Board Of Regents Of The University Of Texas System Oil-based nsaid compositions and methods for making and using same
US8729124B2 (en) 2002-03-05 2014-05-20 Pronova Biopharma Norge As Use of EPA and DHA in secondary prevention
EP1488785A1 (de) 2003-06-18 2004-12-22 B. Braun Melsungen Ag Ölemulsion zur postnatalen Hormonsubstitution
IL158552A0 (en) * 2003-10-22 2004-05-12 Enzymotec Ltd Lipids containing omega-3 fatty acids
US8557861B2 (en) * 2004-09-28 2013-10-15 Mast Therapeutics, Inc. Low oil emulsion compositions for delivering taxoids and other insoluble drugs
PT1868614E (pt) 2005-03-24 2012-11-23 Univ Emory Regime de dosagem para o tratamento de uma lesão cerebral traumática com progesterona
US7473687B2 (en) 2005-03-24 2009-01-06 Emory University Methods for the treatment of a traumatic central nervous system injury
JP2009502745A (ja) 2005-07-08 2009-01-29 マーテック バイオサイエンシーズ コーポレーション 認知症および前認知症に関連した状態を治療するための多価不飽和脂肪酸
CA2631497C (en) 2005-12-05 2014-04-22 Bioartificial Gel Technologies Inc. Emulsions of a protein-crosslinked hydrogel matrix and dispersed hydrophobic phase
WO2007080515A1 (en) 2006-01-13 2007-07-19 Aker Biomarine Asa Thrombosis preventing krill extract
JP5352961B2 (ja) * 2006-03-28 2013-11-27 Jnc株式会社 生活習慣病予防・治療剤
CN101152186B (zh) 2007-09-05 2011-07-06 杭州平和安康医药科技有限公司 黄体酮注射液及其制备方法
US8241672B2 (en) * 2009-03-11 2012-08-14 Stable Solutions Llc Omega-3 enriched fish oil-in-water parenteral nutrition emulsions
RU2009145010A (ru) * 2009-12-04 2011-06-20 Общество с ограниченной ответственностью (ООО) "Аббифарм" (RU) Композиция омега-3 и омега-6 полиненасыщенных жирных кислот
TW201138782A (en) 2010-04-26 2011-11-16 Besins Healthcare Lu Sarl Low-oil pharmaceutical emulsion compositions comprising progestogen
US8895074B2 (en) * 2011-06-15 2014-11-25 Stable Solutions Llc Therapeutic application of parenteral krill oil
CN102277237B (zh) * 2011-06-20 2013-04-24 山东禹王制药有限公司 一种甘油酯型鱼油的制备方法

Also Published As

Publication number Publication date
RU2014139008A (ru) 2016-04-20
ES2659466T3 (es) 2018-03-15
WO2013127728A1 (en) 2013-09-06
MX356427B (es) 2018-05-29
US9789122B2 (en) 2017-10-17
KR20140131936A (ko) 2014-11-14
WO2013127727A1 (en) 2013-09-06
CA2865030C (en) 2021-04-27
EP2819650A1 (en) 2015-01-07
CN110251463A (zh) 2019-09-20
MX2014010442A (es) 2014-10-13
JP2015508792A (ja) 2015-03-23
IL233760A0 (en) 2014-09-30
RU2678319C2 (ru) 2019-01-28
EP2819649B1 (en) 2018-01-10
PL2819649T3 (pl) 2018-06-29
CN104136007A (zh) 2014-11-05
NO2819649T3 (enrdf_load_stackoverflow) 2018-06-09
KR20140131937A (ko) 2014-11-14
BR112014021390A2 (pt) 2019-09-24
CN104136008A (zh) 2014-11-05
JP6169110B2 (ja) 2017-07-26
RU2014138996A (ru) 2016-04-20
IL233759B (en) 2019-01-31
IN2014DN08089A (enrdf_load_stackoverflow) 2015-05-01
US20150018320A1 (en) 2015-01-15
MX2014010445A (es) 2014-10-13
CA2864945A1 (en) 2013-09-06
US20150011515A1 (en) 2015-01-08
PT2819649T (pt) 2018-02-19
JP2015508791A (ja) 2015-03-23
KR102027613B1 (ko) 2019-10-01
BR112014021391A2 (enrdf_load_stackoverflow) 2017-06-20
EP2819649A1 (en) 2015-01-07
IL233759A0 (en) 2014-09-30
BR112014021391B1 (pt) 2022-07-26
CA2865030A1 (en) 2013-09-06

Similar Documents

Publication Publication Date Title
IN2014DN08088A (enrdf_load_stackoverflow)
IN2014DN06125A (enrdf_load_stackoverflow)
EA201890852A1 (ru) Соли валбеназина и их полиморфы
MX2014015004A (es) Inhibidores de bromodominio de benzo [c] isoxazoloazepina y sus usos.
MY188027A (en) Fat composition and fat blend
WO2014152029A3 (en) Oxazolo[5,4-c]quinolin-2-one compounds as bromodomain inhibitors
WO2011097276A8 (en) Methods and compositions for treating arthritis with docosahexaenoic acid
NZ716341A (en) Glyceride composition
EP2560633A4 (en) INTRAVENOUS OMEGA-3 FATTY ACID COMPOSITIONS AND METHOD OF USE THEREOF
MX363993B (es) Composiciones farmaceuticas con actividad hidratante y lubricante.
IL246254A0 (en) Compounds of omega-3 fatty acids for the treatment of diseases involving damage to the nervous system
FI3177281T3 (fi) Rasvahappojen ja palmitoyylietanoliamidin seos käytettäväksi tulehduksellisten ja allergisten patologioiden hoitoon
BR112014031306A2 (pt) composição farmacêutica e respectivos usos
MX2016005900A (es) Profarmaco mutuo que comprende acidos grasos de cadena corta y zebularina o 1'-ciano-citarabina para tratamiento del cancer.
MX364188B (es) Composicion de tratamiento para cabello.
BR112015001694A2 (pt) uso de uma composição para a fabricação de um medicamento para tratamento de distúrbios cutâneos e/ou distúrbios de proliferação celular anormal; composição; e método para preparar uma composição farmacêutica
MY182553A (en) Pharmaceutical compositions comprising 7-(1h-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions
IL239512B (en) Analogues and derivatives of alkyl fatty acids, pharmaceutical formulations containing them and their uses
EA201492238A1 (ru) Композиция мизопростола
MX2016013680A (es) Métodos y composiciones para el tratamiento de trastornos por el almacenamiento de lípidos.
EA201692398A1 (ru) Гомогенная композиция для перорального введения, содержащая омега-3 полиненасыщенные жирные кислоты и ресвератрол
PH12013501910B1 (en) Solid ambroxol-containing preparation
WO2014031034A8 (ru) Фармацевтические композиции, содержащие ипидакрин и их применение для лечения нарушений потенции и других форм половой активности
CR20140350A (es) Composiciones enriquecidas con dpa de ácidos grasos omega 3 poliinsaturados en forma de ácido libre
UA94869C2 (ru) Применение липофлавона в качестве средства для лечения острой черепно-мозговой травмы